Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025

Annexon, Inc.

2024-Q3 EPS reported -$0.68

Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.
Cash and investments $340.1M, expected to fund operations into H2 2026.
R&D expenses rose to $30.1M from $27.9M, driven by GBS, GA, and ANX1502 programs.
ANX005 GBS: topline RWE comparability data expected year-end 2024; BLA submission targeted H1 2025.
Strengthened commercial and medical affairs leadership with three senior appointments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.